COMMUNIQUÉS West-GlobeNewswire

-
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
22/04/2025 - 15:20 -
NewGen Filed 2024 Annual Report on Form 20-F
22/04/2025 - 15:26 -
Konica Minolta Healthcare Partners with openDoctor to Deliver Best-in-Class Patient Engagement
22/04/2025 - 15:36 -
U.S. Oral Surgery Management Announces Partnership with Douglas J. Valentine DDS Oral & Maxillofacial Surgery
22/04/2025 - 15:45 -
Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm
22/04/2025 - 16:00 -
Andrew Taylor joins Novonesis’ Executive Leadership Team
22/04/2025 - 17:00 -
CARBOGEN AMCIS Shanghai Site Awarded Drug Manufacturing License from Chinese NMPA
22/04/2025 - 11:16 -
Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025
22/04/2025 - 11:30 -
Prime Biome Reviews 2025: Updated Comprehensive Guide to the Revolutionary Gut & Skin Health Supplement!
22/04/2025 - 11:33 -
PrimeBiome Reviews: “Gut–Skin Miracle” or Just Hype? Expert Insights
22/04/2025 - 11:42 -
Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
22/04/2025 - 12:00 -
AscellaHealth Demonstrates Leadership in Realizing the Full Potential of Novel Therapies and Medicinal Products at Advanced Therapies Integrates North 2025
22/04/2025 - 12:00 -
R3 Vascular Announces First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using MAGNITUDE® Drug Eluting Bioresorbable Scaffold
22/04/2025 - 12:00 -
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
22/04/2025 - 12:45 -
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
22/04/2025 - 12:55 -
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody
22/04/2025 - 12:59 -
EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual Meeting
22/04/2025 - 13:00 -
PolyPid to Participate in The Citizens Life Sciences Conference
22/04/2025 - 13:00 -
Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
22/04/2025 - 13:00
Pages